Skip to content

Automated Oxygen Delivery by O2matic to Patients Admitted With an Exacerbation in COPD

Automated Oxygen Delivery by O2matic to Patients Admitted With an Exacerbation in COPD

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03464695
Acronym
O2MATIC
Enrollment
20
Registered
2018-03-14
Start date
2018-05-07
Completion date
2018-08-08
Last updated
2026-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD Exacerbation, Copd Exacerbation Acute, Hyperoxia, Hypoxia, Respiratory Failure, Respiratory Insufficiency

Keywords

closed-loop, oxygen treatment

Brief summary

The aim of the study is to examine if automated oxygen delivery with O2matic is better than manually controlled oxygen therapy for patients admitted to hospital with an exacerbation in Chronic Obstructive Pulmonary Disease (COPD). O2matic is a closed -loop system based on continuous non-invasive measurement of pulse and oxygen-saturation that is processed in an algorithm that controls the flow of oxygen to the patient. The primary hypothesis is that O2matic increases time within acceptable oxygen-saturation interval. Secondary hypotheses are that O2matic compared to manual control reduces time with severe hypoxia (SpO2 \< 85 %), hypoxi (SpO2 below intended interval) and hyperoxia (SpO2 above intended interval).

Detailed description

Closed-loop control of oxygen therapy is described in the literature used for preterm infants, trauma patients, medical emergency use and patients with COPD. For the latter, closed-loop therapy has been used for patients admitted to hospital with an exacerbation, for domiciliary oxygen use and during exercise. O2matic is a closed-loop system that is based on continuous and non-invasive measurement of pulse, oxygen-saturation and respiratory frequency. The algorithm in O2matic controls oxygen delivery with the aim of keeping the saturation within the desired interval, which could be 88-92 % for COPD-patients in accordance with international guidelines on this topic. Saturation interval can be set for the individual patients, as can the range of acceptable oxygen-flow. If saturation or oxygen-flow can't be maintained within the desired intervals an alarm will sound. All studies on closed-loop systems have shown that this method is better than manually control by nurse to maintain saturation within the desired interval. Furthermore, some studies have indicated that closed-loop has the possibility to reduce admission time and to reduce time spent with oxygen therapy, due to more efficient and fast withdrawal from oxygen supplementation. In the present study O2matic will be tested versus manual control, for patients admitted with an exacerbation in COPD, and in need of supplemental oxygen. During the study the patients will either have oxygen controlled with O2matic or manually by nursing staff. All patients will have continuous logging of pulse, oxygen-saturation and oxygen-flow with O2matic, but only in the O2matic active group, the algorithm will control oxygen-delivery. The primary hypothesis will be tested, which is that O2matic is better than manual control for maintaining oxygen-saturation within the desired interval and reducing time with unintended hypoxia and hyperoxia. For this purpose 20 patients will be included in a crossover design with 4 hours of O2matic-controlled oxygen treatment and 4 hours with manually titrated oxygen with a 16 hours washout between periods. No safety issues has been reported in the literature. Before use O2matic will be approved by The Danish Medicines Agency, The Ethics Committee in the Capital Region of Denmark and by the regional Data Protection Board. The study will be conducted according to GCP standards with independent monitoring. All adverse events and serious adverse events will be monitored and serious adverse events will be reported to Danish Medicines Agency.

Interventions

DEVICEO2matic

Continous measurement of SpO2 during an admission with COPD, and closed-loop control of oxygen-delivery to maintain SpO2 within a target interval.

Sponsors

Hvidovre University Hospital
Lead SponsorOTHER
Innovation Fund Denmark
CollaboratorINDIV

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
35 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* COPD verified by FEV1/FVC \< 0,70 * Admission due to exacerbation in COPD * COPD exacerbation and pneumonia can be included * Duration of admission \> 48 hours * Need for oxygen supplementation at inclusion (SpO2 \<= 88 % without O2 suppl.) * Cognitively able to participate in the study * Willing to participate and give informed consent.

Exclusion criteria

* Need or anticipated need for mechanical ventilation (except intermittent CPAP) * Major co-morbidities (cancer, heart disease, thromboembolic disease, uncontrolled diabetes) * Asthma or other respiratory condition requiring higher SpO2 than normal for COPD- patients * Pregnancy * Acute thromboembolic disease (\< 2 weeks) * Cognitive barriers for participation

Design outcomes

Primary

MeasureTime frameDescription
Time within SpO2-interval4 hoursFraction of time where SpO2 is kept within desired interval (e.g. 88-92 %) relative to time with SpO2-signal.

Secondary

MeasureTime frameDescription
Time with severe hypoxia4 hoursFraction of time where SpO2 is below 85 % relative to time with SpO2 signal
Time with hypoxia4 hoursFraction of time where SpO2 is below intended interval but not below 85 % relative to time with SpO2 signal
Time with hyperoxia4 hoursFraction of time where SpO2 is above intended interval relative to time with SpO2 signal

Countries

Denmark

Contacts

STUDY_CHAIRJørgen Vestbo, DMSc

Manchester University Hospital

PRINCIPAL_INVESTIGATOREjvind Frausing Hansen, MD

Hvidovre University Hospital, Copenhagen

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 10, 2026